Retatrutide: The Triple Agonist Explained

You’ve probably seen the headlines: a new weight-loss drug that beat almost everything before it in early trials. That drug is retatrutide, and the numbers are genuinely eye-popping. But there’s a catch most articles skip over, so here’s the honest version of what it is, what the science actually shows, how it stacks up against tirzepatide, and why you can’t just buy it.

This is educational information, not medical advice. Retatrutide is investigational. It is not approved by the FDA (or any major regulator) for weight loss, diabetes, or anything else, and it is not legally available by prescription. The semaglutide and tirzepatide drugs it gets compared to are prescription-only and must be supervised by a licensed prescriber. So-called “research” peptides sold online are labeled “for research use only,” are not made for human use, and are not quality-controlled as medicines. Talk to a doctor or pharmacist before you start, change, or stop any medication or dose. Nothing here is an endorsement or instruction to obtain or self-administer an unapproved substance.

Quick answer: Retatrutide is a once-weekly injectable that hits three hormone receptors at once (GLP-1, GIP, and glucagon). In a phase 2 trial, people lost up to about 24% of their body weight in 48 weeks at the highest dose ¹. That’s the most weight loss reported for any obesity drug so far in a trial of its kind. It’s also still in late-stage testing, with phase 3 results and any approval decision still ahead.

What is your main goal?

Lose weight Gain muscles Eat healthy Explore new cuisines

Powered by DietGenie

What is retatrutide?

Retatrutide (you may also see the code name LY3437943) is an experimental drug from Eli Lilly. It belongs to the same broad family as the medications people already know for weight loss, the GLP-1 drugs for weight loss, but it adds a third target.

Most of the approved drugs act on one or two gut hormones. Retatrutide is a triple agonist, meaning one molecule activates three receptors:

• GLP-1 receptor (curbs appetite, slows stomach emptying)
• GIP receptor (another incretin hormone tied to insulin and fat metabolism)
• Glucagon receptor (this is the new one, and it can raise energy expenditure and burn through liver fat)

That glucagon piece is the interesting twist. On its own, glucagon raises blood sugar, which sounds counterproductive. But paired with strong GLP-1 and GIP action, the net effect in trials was more fat loss and a bump in how many calories the body burns, rather than higher blood sugar.

Suggested read: Microdosing GLP-1: What It Means and the Risks

How does retatrutide work in the body?

Think of it as three levers being pulled together. Appetite signaling, the speed food moves through your gut, and energy burn all shift in the same direction.

• Appetite goes down. Like other drugs in this class, retatrutide makes you feel full sooner and stay full longer. People simply eat less without white-knuckling it.
• Energy burn may go up. The glucagon arm is thought to nudge resting energy expenditure higher, which is something pure GLP-1 drugs don’t really do.
• Liver fat drops. Early data showed large reductions in liver fat, which matters for fatty liver disease (a common companion to obesity).

If you want the underlying biology of why your body fights weight loss in the first place, our piece on hormones and weight gives the bigger picture, and the same appetite pathways are why natural appetite suppressants work, just far more gently.

What did the retatrutide weight loss trials show?

The headline data comes from a phase 2 trial published in 2023. Adults with obesity were randomized to placebo or various retatrutide doses and followed for 48 weeks. At the top dose (12 mg weekly), mean weight loss reached roughly 24% ¹. To put that in context, a big chunk of participants lost a quarter of their starting body weight, territory that used to belong only to bariatric surgery.

A few things worth keeping in mind about those results:

• It was a phase 2 trial, designed mainly to test doses and safety, with a few hundred participants, not the tens of thousands you’d see in a definitive phase 3 program.
• Weight loss was still trending downward at 48 weeks, meaning people hadn’t fully plateaued yet.
• The most common side effects were gastrointestinal: nausea, diarrhea, constipation, and vomiting, the same pattern seen across this whole drug class ².

These are promising numbers, but a phase 2 result is a starting line, not a finish line. Large phase 3 trials are what regulators rely on, and those determine whether the early magic holds up across a much bigger, more varied population.

Suggested read: Tirzepatide Side Effects: GI, Risks & Hair Loss

Retatrutide vs tirzepatide: how do they compare?

This is the comparison everyone wants, because tirzepatide (Mounjaro, Zepbound) is the current heavyweight and it’s already approved. The honest framing: you can’t directly compare across separate trials, because the study designs, populations, and durations differ. But the ballpark figures are still useful.

So on paper retatrutide edges out tirzepatide, and it did it in less time (48 vs 72 weeks). The extra glucagon target is the leading theory for that gap. But “looks better in a smaller, shorter trial” is not the same as “proven better,” and only tirzepatide is something a doctor can actually prescribe you today. If you’re weighing the approved options, our breakdown of semaglutide vs tirzepatide and the tirzepatide dosage guide are the practical place to start.

Is retatrutide available, and what’s the dose?

Short version: no, you can’t legally get retatrutide for weight loss. It’s still in clinical trials. There is no approved prescription product, no pharmacy that stocks it as a medicine, and no FDA-sanctioned dosing schedule for the public.

When people talk about a “retatrutide dose,” they’re usually quoting the trial regimens, which used a slow upward titration starting around 1–2 mg weekly and climbing over months to 8 or 12 mg. Those schedules ran inside a monitored clinical setting with medical oversight, blood work, and dose adjustments. They are not a recipe to copy at home.

This is exactly where the danger sits. Because retatrutide isn’t sold as a medicine, the only places offering it are “research chemical” vendors, and that opens a long list of problems.

Suggested read: Compounded Semaglutide and Tirzepatide: Safe?

The real risks of buying “research” retatrutide online

I’ll be blunt here, because the marketing online is slick and the framing (“research use only,” “not for human consumption”) is a legal fig leaf, not a safety guarantee. The risks are stacked against you:

• You don’t know what’s in the vial. No regulator checks these products. Independent testing of gray-market peptides regularly turns up wrong doses, degraded product, contaminants, or the wrong compound entirely. Our overview of whether peptides are safe walks through what actually goes wrong.
• The legal status is murky and risky. Selling unapproved drugs for human use is illegal, which is why everything is labeled “research only.” Read are peptides legal before you assume a purchase is harmless.
• No medical supervision. This drug class can cause significant nausea and vomiting, gallbladder problems, pancreatitis in rare cases, and it carries contraindications (like a personal or family history of medullary thyroid cancer) ². Trials screen people out and monitor them. A website does neither.
• Dosing errors are easy and consequential. Reconstituting and measuring an injectable correctly is genuinely hard to get right, and a math slip can mean a many-fold overdose.
• Muscle loss is a hidden cost. Rapid weight loss on these drugs can strip lean mass, not just fat, unless you actively protect it with protein and resistance training ⁴. Without guidance, a lot of “research” users lose muscle they’ll regret.

If you’re determined to understand the mechanics anyway, here is a reconstitution calculator, included strictly for educational understanding of the math involved, not as encouragement to self-administer anything.

For more on doing this math (again, as background, not a how-to for unapproved drugs), see the dedicated peptide dosage calculator page.

Suggested read: Natural GLP-1: Foods and Habits That Raise It

Why the hype needs a reality check

The triple-agonist idea is legitimately exciting, and retatrutide may well become a major drug if phase 3 confirms the early data. The whole class has already shown it does more than shrink waistlines, semaglutide cut major cardiovascular events by about 20% in a large obesity trial ⁵, which hints that these medications affect long-term health, not just the scale.

But three sober points:

1. Approved beats experimental. Drugs you can get with supervision, like semaglutide and tirzepatide, already deliver dramatic results with a known safety profile.
2. Trial numbers shrink in the real world. Adherence, side effects, and individual variation always pull average results down outside a controlled study.
3. No drug replaces the basics. Protein intake, resistance training, fiber, and sleep all decide how much of your loss is fat versus muscle and whether it lasts.

Bottom line

Retatrutide is the most powerful obesity drug seen in early trials so far, a true triple agonist that produced up to ~24% weight loss in 48 weeks ¹. That’s a real scientific milestone. But it is still investigational, not legally available, and the “research” versions sold online are an unregulated gamble with your health. If you want results you can actually act on, the smart move is talking to a doctor about approved, supervised options, and pairing whatever you do with the unglamorous fundamentals that protect your muscle and keep the weight off. Retatrutide is one to watch, not one to chase.